Noriko Nishimura, MD, PhD

Advanced Clinical Fellow
The Precision Cellular Therapy Laboratory
Publications
Jobs
Members

Noriko Nishimura, MD, PhD

Advanced Clinical Fellow
Share
Share
Noriko Nishimura

I am a Hematologist/Oncologist currently serving as an advanced clinical fellow in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). I earned my Ph.D. researching the mechanisms of action of imatinib and have since dedicated my efforts to precision medicine, particularly in the treatment of multiple myeloma and malignant lymphoma. My work involves investigating the fundamental mechanisms driving disease progression through clinical trials and translational research. Presently, my research focuses on the impact of minimal residual disease on myeloma survival and the independent prognostic factors of CAR-T cell therapy in both myeloma and lymphoma.

Publications

Stem cell autograft minimal residual disease negativity improves outcomes after autologous hemopoietic stem cell transplant for multiple myeloma, preparing for submission

Noriko Nishimura, Samantha Brown, Sean M. Devlin, Parastoo Dahi, Heather J. Landau, Oscar B. Lahoud, Michael Scordo, Gunjan L. Shah, Sridevi Rajeeve, Hani Hassoun, Malin Hultcrantz, Neha Korde, Alexander M. Lesokhin, Sham Mailankody, Urvi A. Shah, Carlyn R. Tan, Gaurav Gupta, Elena Maryamchik, Evangelos Ntrivalas6, Mikhail Roshal, Saad Z. Usmani, Sergio A. Giralt, David J. Chung

MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era. Leuk Res. 2020 Oct;97:106426. PubMed ID: 32781214.Nishimura N, Takeuchi K, Asaka R, Tuyama N, Inoue N, Kusano Y, Mishima Y, Yokoyama M, Terui Y.

Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. Oncogene. 2003 Jun 26;22(26):4074-82. PubMed ID: 12821941.Nishimura N, Furukawa Y, Sutheesophon K, Nakamura M, Kishi K, Okuda K, Sato Y, Kano Y.